Vroeg-screening voor mesothelioom

28-10-2008

Volgens Van Meerbeeck en Hillerdal is vroeg-screening voor de ziekte mesothelioom op dit moment nog niet zinvol.
De nieuwste diagnostische scantechnieken (CT/PET) en bloedtests (SMRP-ELISA) zijn nog niet voldoende nauwkeurig. Verder is er nog geen bewijs dat vroeg-ontdekking van deze ziekte de levensduur kan verlengen of de patiënt kan genezen. Bron:
Meerbeeck, J.P. van & Hillerdal, G. (2008). Screening vor mesothelioma. More harm than good? American Journal of Respiratory and Critical Care Medicine, vol178, pp 781-82.

Britse voorlichtingscampagne over asbest

27-10-2008

De Britse ‘Health and Safety Executive’ is een campagne gestart om middenstanders bewust te maken van de risico’s van asbest. Momenteel overlijden in het Verenigd Koninkrijk elke week 20 middenstanders aan een asbestgerelateerde ziekte. Bron: Hse, 22 oktober 2008 .

Rechtbank Almelo: Nefalit aansprakelijk

27-10-2008

Nefalit BV (voorheen Asbestona) is aansprakelijk voor het ontstaan van de ziekte mesothelioom bij een boer uit Beilen die in 1979 bij het verzagen van asbestcementgolfplaten aan asbeststof was blootgesteld.
Het bedrijf had namelijk verzuimd klanten te waarschuwen voor de destijds aan haar bekende gezondheidsrisico’s die met het verzagen van deze producten zijn verbonden. Bron: Rechtbank Almelo, 9 juli 2008: 85355 HA ZA 07-344.

Exxon aansprakelijk

27-10-2008

Oliemaatschappij Exxon was al in 1937 op de hoogte van de gevaren van de asbest die voorkwam op haar rivierboten, in haar chemische fabrieken en olie-raffinaderijen, maar verzuimde haar werknemers te beschermen.
Het bedrijf is daarom aansprakelijk voor de ziekte mesothelioom bij een man die tussen 1945 en 1949 in de de machinekamer van één van de boten had gewerkt, oordeelt het ‘Louisiana First Court of Appeal’. Bron: Oncology Business Week, 19 oktober 2008.

Canada: veel verborgen asbestslachtoffers

23-10-2008

In Canada worden steeds meer gevallen van mesothelioom geregistreerd, zonder dat er een relatie met asbest wordt gelegd.
Dit blijkt uit een vergelijking van cijfers van de Canadese Kankerregistratie met het aantal aanvragen voor compensatie via de Workplace Safety and Insurance Board. Wetenschappers schatten het aantal gevallen van mesothelioom in het district Ontario momenteel op 500 per jaar. In 2007 werden daar slechts 29 claims voor compensatie goedgekeurd. Bron: The Toronto Star, 20 september 2008.

Overzichtsstudies asbestziekten

23-10-2008

Franse en Amerikaanse onderzoekers beschrijven in twee overzichtsartikelen de ontwikkelingen in de diagnostiek en behandeling van asbestgerelateerde ziekten, waaronder mesothelioom.

 

Greillier, L. & Astoul, P. (2008). Mesothelioma and asbestos-related pleural diseases. Respiration. 2008;76(1):1-15. 
ABSTRACT
At present, the use of asbestos is not regulated at a worldwide scale. Moreover, there is a latency period between asbestos exposure and the manifestations of asbestos-related diseases. Consequently, pulmonologists are still dealing with consequences of asbestos exposure, which mainly occur at the pleural surface. The aim of this review is to provide an overview of asbestos-related pleural diseases. We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis. Special attention is dedicated to malignant pleural mesothelioma, given the challenging issues of this disease, the recent advances in its management and the dynamism of research in this area.

Zervos, M.D. et al. (2008). Malignant mesothelioma 2008.Curr Opin Pulm Med. 2008 Jul;14(4):303-9. 
ABSTRACT
PURPOSE OF REVIEW: Mesothelioma is an aggressive malignancy of the pleura with poor survival. There will be approximately 3000 cases of mesothelioma in the United States annually. Multimodality treatment including neoadjuvant chemotherapy in selected individuals followed by extrapleural pneumonectomy and radiation has been studied in recent trials for its effects on disease free and overall survival This review provides a general overview of malignant mesothelioma with a summary of the most significant articles from within the past year as well as from the past. RECENT FINDINGS: Areas of recent interest include the evaluation of osteopontin and mesothelin as new tumor markers for mesothelioma. New phase III trials have been performed to evaluate the use of combined chemotherapy regimens. SUMMARY: Malignant mesothelioma is a very difficult malignancy to treat. Patients with the disease usually have an occupational asbestos exposure, and in some, viral exposure with SV40. There have been many historical treatments including combinations of local control with surgery and radiation as well as attempts to prevent systemic failure with chemotherapy. Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success. Finally there are several attempts at immunomodulating and targeted treatments, which are in phase I/II trials.

SV40-virus veroorzaakt mesothelioom

23-10-2008

Volgens Rivera et al., is er voldoende bewijs om aan te nemen dat het simian 40 virus de ziekte mesothelioom kan veroorzaken: zowel alleen als in combinatie met asbestcontact.
Het bewijs is echter nog onvoldoende om te kunnen bepalen in welke mate het virus oorzaak is van deze ziekte. Het sv40 virus was oorspronkelijk een virus dat alleen bij apen voorkwam, maar bleek per abuis in de jaren 60 van de vorige eeuw ook in het poliovaccin te zitten.
Bron: Rivera, Z. et al. (2008). The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med. 2008 Jul;14(4):316-21.
ABSTRACT
PURPOSE OF REVIEW:
Simian virus 40 is present in some human malignant mesotheliomas. The evidence in favor and against a pathogenic role of simian virus 40 in malignant mesothelioma is discussed in this review.
RECENT FINDINGS: When simian virus 40 is injected intracardially into hamsters, 60% develop and die of malignant mesothelioma. Moreover, some human malignant mesotheliomas contain and express simian virus 40 DNA and proteins. To date, over 50 laboratories have detected simian virus 40 in malignant mesotheliomas and in other tumors; however, the variability of the percentage of positivity led to a controversy about the role and significance of simian virus 40 in malignant mesotheliomas. Compared with other cell types, human mesothelial cells are unusually susceptible to simian virus 40-induced malignant transformation. The presence of simian virus 40 in malignant mesothelioma has been associated with the activation of specific oncogene pathways. Cocarcinogenesis between simian virus 40 and asbestos in causing malignant mesotheliomas has been demonstrated in three separate research laboratories using different experimental approaches. Epidemiological data possibly linking simian virus 40 and malignant mesothelioma is lacking owing to unattainable identification of infected from noninfected cohorts.
SUMMARY: Available evidence appears sufficient to link simian virus 40 either alone or in conjunction with asbestos in causing malignant mesotheliomas; however, it is still insufficient to speculate about the contribution of simian virus 40 to the overall incidence of malignant mesotheliomas.

Levensverwachting

02-10-2008

Moshammer en Neuberger concluderen dat de verslechtering van de conditie van de longen een betere voorspeller is van de levensverwachting is dan de kennis over de hoeveelheid asbest waaraan iemand is blootgesteld. Volgens Christensen et al. is er een relatie tussen het aantal asbestvezels dat in de longen aangetroffen wordt en de levensverwachting van een mesothelioompatiënt.
Bron: Moshammer, H. & Neuberger, M. (2008). Lung function predicts survival in a cohort of asbestos cement workers. Int Arch Occup Environ Health. 2008 Apr 12. ABSTRACT

PURPOSE: To study the predictive power of respiratory screening examinations a cohort of asbestos workers was followed from active work in an asbestos cement plant until death.

METHODS: From a cohort with data on individual exposure since first employment 309 workers who had a preventive medical examination in 1989/1990 were observed until death or the end of 2006. The impact of asbestos exposure (fibre years) and of smoking history on lung function was examined by linear regression, on specific causes of death and total mortality by Cox regression. The prognostic value of lung function, chest X-ray, and various clinical findings regarding total mortality was also examined by Cox regression.

RESULTS: Lung function proved to be the best predictor of survival apart from current smoking. Depending on the lung function variable an impairment by the interquartile range resulted in a hazard ratio of 1.5-1.6 while for current smokers it was 2.3. An increase of 70 fibre years (interquartile range) led to a hazard ratio of only 1.1. Lung function was influenced by asbestos exposure, current (but not former) smoking, and by pathological X-ray findings. The risk for pleural mesothelioma was dominated by time since first exposure to crocydolite in the pipe factory while the risk for bronchial cancer increased with smoking and total fibre years. An unexpected finding was an increase of gastric cancer in asbestos cement workers.

CONCLUSION: Lung function decrease predicts risk of premature death better than exposure history and regular spirometry should therefore be offered as primary screening to all former asbestos workers. In workers with a history of high cumulative exposure or rapid lung function decrease or radiological signs (diffuse pleural thickening or small irregular opacities) more sensitive techniques (high resolution computer tomography) need to be applied. All smokers with a history of asbestos exposure should be given free smoking cessation therapy to prevent premature death and lung cancer in particular.

Bron: Christensen, B.C. et. al. (2008). Asbestos burden predicts survival in pleural mesothelioma. Environmental  Health Perspectives, Jun;116(6):723-6.

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rapidly fatal asbestos-associated malignancy with a median survival time of <1 year following diagnosis. Treatment strategy is determined in part using known prognostic factors. OBJECTIVE: The aim of this study was to examine the relationship between asbestos exposure and survival outcome in MPM in an effort to advance the understanding of the contribution of asbestos exposure to MPM prognosis. Methods: We studied incident cases of MPM patients enrolled through the International Mesothelioma Program at Brigham and Women's Hospital in Boston, Massachusetts, using survival follow-up, self-reported asbestos exposure (n=128), and a subset of cases (n=80) with quantitative asbestos fiber burden measures. Results: Consistent with the established literature, we found independent, significant associations between male sex and reduced survival (p<0.04), as well as between nonepithelioid tumor histology and reduced survival (p<0.02). Although self-reported exposure to asbestos was not predictive of survival among our cases, stratifying quantitative asbestos fiber burden [number of asbestos bodies per gram of lung (wet weight)] into groups of low (0-99 asbestos bodies), moderate (100-1,099), and high fiber burden (>1,099), suggested a survival duration association among these groups (p=0.06). After adjusting for covariates in a Cox model, we found that patients with a low asbestos burden had a 3-fold elevated risk of death compared to patients with a moderate fiber burden [95% confidence interval (CI), 0.95-9.5; p=0.06], and patients with a high asbestos burden had a 4.8-fold elevated risk of death (95% CI, 1.5-15.0; p<0.01) versus those with moderate exposure. Conclusion: Our data suggest that patient survival is associated with asbestos fiber burden in MPM and is perhaps modified by susceptibility.

Kosten asbestschip Otapan

02-10-2008

De Nederlandse staat krijgt de meer dan 5 miljoen kosten voor de sanering van het asbestschip de Otapan mogelijk niet volledig terug. Een schikking met de voormalige Mexicaanse eigenaar van het schip ,,behoort tot de mogelijkheden”, zei milieuminister Jacqueline Cramer op 23 september j.l. in de Tweede Kamer.